Health Care & Life Sciences » Pharmaceuticals | Bio-Path Holdings Inc.

Bio-Path Holdings Inc.

Bio-Path Holdings Inc.
Stock Exchange NASDAQ Stock Market
EPS
$12.03
Market Cap
$38.22 M
Shares Outstanding
2.83 M
Public Float
1.72 M

Profile

Address
4710 Bellaire Boulevard
Bellaire Texas 77401
United States
Employees -
Website http://www.biopathholdings.com
Updated 07/08/2019
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company utilizing a novel technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its platform DNAbilize, uses P-ethoxy, which is a deoxyribonucleic acid backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in vivo, incorporated inside of a neutral charged lipid bilayer. The company was founded by Peter Nielsen, Douglas P.

Financials

View All
Created with Highcharts 5.0.14Bio-Path Holdings Inc.Net Income. Fiscal year is January-December. All values USD Thousands.3 2663 2664 5194 5195 4665 4666 7506 7507 0237 0238 5838 58320132014201520162017201802k4k6k8k10k
Created with Highcharts 5.0.14Bio-Path Holdings Inc.Sales/Revenue. Fiscal year is January-December. All values USD Thousands.000000131337374264262013201420152016201720180100200300400500

Peter H. Nielsen
Chairman, President, CEO, CFO & Treasurer
Douglas P. Morris
Secretary & Non-Independent Director